Introduction {#s1}
============

During eukaryotic cell division, the spindle assembly checkpoint (SAC) contributes to ensure the accuracy of chromosome segregation. This evolutionarily conserved surveillance mechanism monitors the status of kinetochore (KT)-microtubule (MT) interactions and delays anaphase onset until all chromosomes have undergone bipolar attachment to the spindle. Both KT-MT interactions and SAC activity are regulated by several KT-associated protein kinases, including Aurora B, Monopolar spindle 1 (Mps1) and Budding uninhibited by benzimidazoles 1 (Bub1) ([@bib61]; [@bib65]; [@bib80]). SAC activity depends on a diffusible inhibitor of the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C), termed mitotic checkpoint complex (MCC) ([@bib24]; [@bib53]; [@bib66]; [@bib77]). Once the SAC is silenced in response to chromosome biorientation, APC/C activation then triggers the onset of chromatid separation and mitotic exit, respectively ([@bib26]).

The serine/threonine kinase Bub1 is one of the first proteins to accumulate at unattached kinetochores ([@bib35]). Its recruitment is governed by Mps1-dependent phosphorylation of MELT motifs on the KMN complex member KNL-1 ([@bib60]; [@bib68]; [@bib83]; [@bib97]; [@bib103]). Bub1 has been implicated in the regulation of chromosome cohesion, KT-MT interactions and SAC function. In particular, Bub1 was shown to be important for the centromere/KT recruitment of Shugoshin proteins (Sgo1 and Sgo2), the chromosomal passenger complex (CPC) comprising Aurora B kinase, CENP-E, CENP-F, BubR1, Mad1 and Mad2 ([@bib6]; [@bib46]; [@bib48]; [@bib57]; [@bib69]; [@bib93]).

So far, only few substrates of Bub1 have been identified. Best characterized is the phosphorylation of histone H2A on threonine 120 (T120) ([@bib44]). Phosphorylation of this site by Bub1 can be demonstrated not only in vitro but also in living cells ([@bib44]; [@bib56]; [@bib82]). Histone H2A phosphorylation on T120 triggers the centromere localization of Sgo1, which in turn recruits the CPC subunit Borealin ([@bib44]; [@bib57]; [@bib94]; [@bib102]). Centromere recruitment of the CPC is further enhanced by the kinase Haspin, which phosphorylates histone H3 at T3 and triggers the centromere binding of the CPC component Survivin ([@bib19]; [@bib45]; [@bib100]). Another intriguing potential substrate of Bub1 is the APC/C co-activator Cdc20 ([@bib56]; [@bib86]). Whether Bub1 phosphorylates Cdc20 in living cells remains to be determined, but recent studies strongly suggest that Bub1 binding to Cdc20 is important for SAC function ([@bib17]; [@bib98]).

Genetic, biochemical or siRNA-mediated depletion of Bub1 protein clearly interferes with chromosome alignment and SAC activity, but the importance of Bub1 catalytic activity has long been subject to debate ([@bib5]; [@bib21]; [@bib26]). For example, while a Bub1 mutant completely lacking the kinase domain is checkpoint proficient in *Saccharomyces cerevisiae* ([@bib23]), conflicting data have been reported on the importance of Bub1 kinase activity in fission yeast *Schizosaccharomyces pombe* ([@bib76]; [@bib95]; [@bib104]). Similarly, in *Xenopus* egg extracts, catalytically inactive Bub1 can sustain the SAC ([@bib82]), although kinase-proficient Bub1 may be more efficient ([@bib6]; [@bib12]). In mammalian cells, several studies point to the conclusion that Bub1 mutants devoid of catalytic activity are able to restore many, albeit not all, aspects of chromosome congression and SAC function ([@bib48]; [@bib64]; [@bib70]; [@bib74]).

To address the role of Bub1 kinase activity in mammalian mitosis, we have made use of two novel small molecule inhibitors, BAY-320 and BAY-524. Using biochemical and cellular assays, we show that these ATP-competitive inhibitors potently and specifically block human Bub1 both in vitro and in living cells. By comparing phenotypes provoked by Bub1 kinase inhibition and Bub1 protein depletion, we are able to differentiate between catalytic and non-catalytic functions of Bub1. Our data indicate that Bub1 catalytic activity is largely dispensable for chromosome alignment and SAC function, arguing that Bub1 largely operates as a scaffolding protein. However, even though Bub1 inhibition per se exerts only minor effects on mitotic fidelity, BAY-320 and BAY-524 treatment sensitizes cells to clinically relevant low doses of Paclitaxel, resulting in remarkable impairment of chromosome segregation and cell proliferation.

Results {#s2}
=======

BAY-320 and BAY-524 specifically inhibit Bub1 kinase {#s2-1}
----------------------------------------------------

The chemical synthesis of small molecule inhibitors against Bub1 has recently been described ([@bib31]). In this study, we used the two substituted benzylpyrazole compounds, 2-\[5-cyclopropyl-1-(4-ethoxy-2,6-difluorobenzyl)-4-methyl-1H-pyrazol-3-yl\]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine and 2-\[1-(4-ethoxy-2,6-difluorobenzyl)-5-methoxy-4-methyl-1H-pyrazol-3-yl\]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine, abbreviated as BAY-320 and BAY-524, respectively ([Figure 1A](#fig1){ref-type="fig"}). In vitro inhibition of Bub1 by BAY-320 and BAY-524 was demonstrated by monitoring both Bub1 autophosphorylation and phosphorylation of histone H2A on T120 ([@bib44]) ([Figure 1B](#fig1){ref-type="fig"}). In presence of 2 mM ATP, both compounds inhibited the recombinant catalytic domain of human Bub1 (amino acids 704--1085) with an IC~50~ of 680 ± 280 nM and 450 ± 60 nM, respectively ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). When tested against a panel of 222 protein kinases, BAY-320 showed only modest cross reactivity with other kinases, even when used at a concentration of 10 μM ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Furthermore, quantitative measurements of BAY-320 interactions with 403 human kinases, using an active site-directed competition-binding assay, showed exquisite binding selectivity for Bub1 ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}).10.7554/eLife.12187.003Figure 1.BAY-320 and BAY-524 inhibit Bub1 kinase.(**A**) Chemical structure of ATP-competitive inhibitors BAY-320 and BAY-524. (**B**) In vitro kinase assays showing dose-dependent inhibition of Bub1 kinase activity towards histone H2A. The assays were performed by mixing human wild-type (WT) or kinase-dead (KD) LAP-Bub1, ectopically expressed in and purified from mitotic HEK 293T cells, with recombinantly expressed histone H2A as a substrate, γ-^32^P-ATP and increasing doses of the Bub1 inhibitors BAY-320 and BAY-524. After 30 min at 30°C, reactions were stopped and analyzed by gel electrophoresis. Bub1 autophosphorylation and H2A phosphorylation were visualized by autoradiography (^32^P) and protein levels monitored by Coomassie brilliant blue staining (CBB). Histone H2A-T120 phosphorylation (pT120-H2A) was detected by phospho-antibody probing of Western blots (WB) and Bub1 was monitored as control. (**C, D**) Inhibition of Bub1 reduces histone H2A-T120 phosphorylation. Asynchronous cultures of HeLa S3 (left panels) and RPE1 cells (right panels) were treated with the proteasomal inhibitor MG132 for 2 hr, followed by the addition of 3.3 μM nocodazole and increasing doses of BAY-320 (**C**) or BAY-524 (**D**) for 1 hr. The cells were fixed and analyzed by immunofluorescence microscopy (IFM). Scatter plots show centromeric levels of pT120-H2A (n = 19--28 cells per condition). Bars represent mean values. (**E**) HeLa S3 cells were synchronized by thymidine block, released for 10 hr in the presence of solvent (control), 3 μM BAY-320 or 7 μM BAY-524 and analyzed by quantitative IF (top panels). Cells transfected with mock (Gl2) or Bub1 siRNA-oligonucleotides for 48 hr were synchronized and analyzed in parallel (bottom panels). The cells were stained with antibodies raised against Bub1 and pT120-H2A. Human CREST serum was used to identify centromeres and DNA was stained with DAPI; scale bars represent 10 µm. (**F**) Histograms showing the average signal intensities of centromeric pT120-H2A observed in the experiments described in (**E**); n = 73--107 cells per condition. Error bars represent standard error of the mean (SEM). (**G**) To monitor the efficacy of Bub1 kinase inhibition within cells, HeLa S3 cells were synchronized by thymidine block and released for 14 hr in the presence of 3.3 μM nocodazole as well as Bub1 inhibitors or solvent as indicated. Prometaphase-arrested cells were harvested by shake-off and mitotic cell extracts were treated with or without phosphatase inhibitor for 30 min at 30°C. Histone isolation was followed by Western blot analysis of pT120-H2A. Equal loading was monitored by Ponceau S staining.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.003](10.7554/eLife.12187.003)10.7554/eLife.12187.004Figure 1---figure supplement 1.BAY-320 and BAY-524 inhibit Bub1 kinase. (**A, B**) BAY-320 and BAY-524 treatment coordinately reduces histone H2A-T120 phosphorylation as well as Aurora B centromere/KT binding, until maximal Bub1 inhibition is reached at 10 μM. Asynchronous cultures of HeLa S3 (left panels) and RPE1 cells (right panels) were treated with the proteasomal inhibitor MG132 for 2 hr, followed by the addition of 3.3 μM nocodazole and increasing doses of BAY-320 (**A**) or BAY-524 (**B**) for 1 hr. The cells were fixed and analyzed by immunofluorescence microscopy (IFM). Scatter plots show centromere/KT levels of pT120-H2A and Aurora B (n = 19--28 cells per condition). Bars represent mean values. (**C**) Untreated HeLa cells (red) or HeLa cells treated with nocodazole for 16 hr, followed by various concentrations of BAY-320 (green) or solvent (black) for 1 hr, were fixed and analyzed by quantitative in-cell western. Plot shows total pT120-H2A signal intensity. Grey area highlights the concentration range between 3 and 10 μM. The IC~50~ (reflecting the inhibition of Bub1 kinase activity compared to control and normalized to cell number) was determined to be 379 +/- 156 nM.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.004](10.7554/eLife.12187.004)

To test whether BAY-320 and BAY-524 also inhibit Bub1 in intact cells, increasing doses of inhibitors were applied to mitotically synchronized hTERT-RPE1 (RPE1) and HeLa cells, and phospho-histone H2A-T120 staining at kinetochores was monitored by immunofluorescence ([Figure 1C--F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A, B](#fig1s1){ref-type="fig"}) and in-cell western assays ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). These studies revealed that near-maximal inhibition of Bub1 could be achieved by using BAY-320 at 3--10 μM and BAY-524 at 7--10 μM and these concentrations were therefore used in all future experiments on intact cells. To corroborate the above immunofluorescence data, histones were purified from control and inhibitor-treated cells. Examination of histone H2A phosphorylation by Western blotting revealed that treatment of cells with either BAY-320 or BAY-524 drastically reduced T120 phosphorylation ([Figure 1G](#fig1){ref-type="fig"}). Thus, BAY-320 and BAY-524 act as potent and selective inhibitors of Bub1 kinase in both biochemical and cellular assays and thus constitute attractive tools to study Bub1 catalytic function during mitosis.

Impact of Bub1 kinase inhibition and Bub1 depletion on mitotic progression {#s2-2}
--------------------------------------------------------------------------

Next, we set out to directly compare the impact of Bub1 kinase inhibition with the previously reported consequences of Bub1 depletion ([@bib6]; [@bib40]; [@bib46]; [@bib48]; [@bib59]; [@bib65]; [@bib87]) or genetic Bub1 knock-out ([@bib37]; [@bib70]; [@bib69]; [@bib74]). In a first series of experiments, we used time-lapse imaging to compare progression through mitosis in asynchronously growing HeLa and RPE1 cells in response to either Bub1 inhibition or siRNA-mediated Bub1 depletion. In line with previous results ([@bib46]; [@bib87]), depletion of Bub1 from HeLa cells significantly prolonged duration of mitosis, due to delayed chromosome alignment and delays in prometa- and metaphase ([Figure 2A and C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In stark contrast, treatment with either BAY-320 or BAY-524 provoked at most minor effects on mitotic progression, marked by a short delay of anaphase onset ([Figure 2B and C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B and C](#fig2s1){ref-type="fig"}). Furthermore, in contrast to aneuploid HeLa cells, diploid RPE1 cells were not significantly affected by either Bub1 inhibition or depletion ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Efficiency of siRNA-mediated depletion was monitored by Western blotting ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). Flow-cytometric analyses confirmed that Bub1 depletion from HeLa cells causes an increase in the G2/M population of HeLa but not RPE1 cells and that Bub1 inhibition by BAY-320 or BAY-524 did not detectably affect cell cycle profiles in either cell line ([Figure 2---figure supplement 1F and G](#fig2s1){ref-type="fig"}). We conclude that the inhibition of Bub1 kinase activity in either HeLa or RPE1 cells produces at most subtle effects on mitotic progression, whereas Bub1 depletion exerts more profound effects, at least in HeLa cells. These results are consistent with the demonstration that Bub1 kinase activity is not required for the development and viability of mice ([@bib71]; [@bib74]).10.7554/eLife.12187.005Figure 2.Inhibition of Bub1 kinase activity barely affects mitotic progression.(**A, B**) Representative stills from time-lapse recordings of asynchronously growing cultures of HeLa S3 cells stably expressing GFP-tagged histone H2B. The cells were either treated with Bub1 inhibitors (3 μM BAY-320 and 7 μM BAY-524) or transfected with control (Gl2) or Bub1 siRNA for 48 hr prior to time-lapse microscopy. Scale bars represent 10 µm. (**C, D**) Graphs show the cumulative frequency of mitotic duration determined by cell rounding/flattening. Indicated averages represent the time spent in mitosis (n = 100 cells per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.12187.005](10.7554/eLife.12187.005)10.7554/eLife.12187.006Figure 2---figure supplement 1.Inhibition of Bub1 kinase activity barely affects mitotic progression. (**A, B**) Representative stills from time-lapse recordings described in [Figure 2](#fig2){ref-type="fig"}. Micrographs show fluorescence or DIC images of HeLa S3 cells stably expressing GFP-tagged histone H2B. Time is indicated relative to mitotic entry. (**C, D**) Hela S3 cells stably expressing GFP-H2B were treated with solvent (control) or Bub1 inhibitors at indicated doses and monitored by fluorescence time-lapse imaging. Dot plots show the time from mitotic entry to anaphase onset; bars represent mean values (n = 80 cells per condition). (**E**) Representative Western blots show Bub1 depletion efficiencies. Asynchronous cultures of HeLa S3 or RPE1 cells were transfected with control (Gl2) or Bub1 siRNA-oligonucleotides for 48 hr, harvested and analyzed by Western blotting; α-tubulin served as loading control. (**F, G**) Cell cycle distribution of exponentially growing HeLa S3 (**F**) and RPE1 (**G**) cells upon treatment with solvent (control), 3 μM BAY-B320, 7 μM BAY-B524 or after Bub1 protein depletion (siGl2 served as control). After 48 hr of treatment or siRNA oligonucleotide transfection cells were permeabilized and DNA was stained with propidium iodide. Cellular DNA content was determined using flow cytometry and frequencies of G1, S and G2/M phases were determined. Considering that Bub1 inhibition did not influence cell cycle profiles in HeLa and RPE1 cells and that the increase in the G2/M population after depletion of Bub1 from HeLa cells correlated with an increase in mitotic duration ([Figure 2](#fig2){ref-type="fig"}), we anticipate that the increase in the corresponding G2/M population mostly reflects mitotic cells.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.006](10.7554/eLife.12187.006)

Bub1 kinase regulates Shugoshin localization and chromatid cohesion {#s2-3}
-------------------------------------------------------------------

One of the most interesting effects of Bub1 depletion described so far relates to sister chromatid cohesion ([@bib6]; [@bib23]; [@bib46]; [@bib87]). In particular, depletion of Bub1 was shown to cause persistent arm cohesion and a redistribution of Sgo proteins from centromeres to chromosome arms ([@bib46]). To directly demonstrate a role for Bub1 kinase activity in sister chromatid cohesion, we analyzed chromosome spreads prepared from mitotic HeLa cells or RPE1 cells after treatment with Bub1 inhibitors ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) or Bub1-specific siRNA for comparison ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). While mitotic chromosome spreads from nocodazole-treated control cells showed the expected X-shape structure, indicative of centromere cohesion, most cells treated with either Bub1 inhibitors or Bub1 siRNA showed sister chromatids whose arms remained paired ([Figure 3A--C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Moreover, centromeric levels of Sgo1 and Sgo2 were reduced to \~20% of control values in BAY-320 or BAY-524 treated cells ([Figure 3D and E](#fig3){ref-type="fig"}) and, concomitantly, a significant redistribution of Sgo2 to chromosome arms could be observed ([Figure 3F and G](#fig3){ref-type="fig"}). We thus conclude that Bub1 catalytic activity contributes to the regulation of sister chromatid cohesion and the localization of Sgo proteins.10.7554/eLife.12187.007Figure 3.Inhibition of Bub1 affects Sgo1 and Sgo2 localization and chromatid cohesion.(**A, B**) HeLa S3 cells were synchronized by thymidine block and released for 12 hr in the presence of 3.3 μM nocodazole as well as solvent (control), 3 μM BAY-320 or 7 μM BAY-524. Cells transfected with mock (Gl2) or Bub1 siRNA-oligonucleotides for 48 hr were synchronized and analyzed in parallel. Micrographs show representative chromosome spreads prepared from mitotic cells. Insets show magnifications of chromosomes; they illustrate representative chromatid cohesion states. (**C**) Quantification of results of the experiments described in (**A**) and (**B**) as well as [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; n = 200 cells per condition. (**D**) HeLa S3 cells were released from a thymidine arrest into solvent, 3 μM BAY-320 or 7 μM BAY-524. The cells were fixed and stained for Sgo1, Sgo2, CREST and DNA (DAPI) and analyzed by IFM. Scale bars represent 10 µm. (**E**) Histogram showing average centromeric Sgo levels observed in the experiments described in (**A**); n = 43--120 cells per condition. Error bars represent SEM. (**F**) Asynchronous cultures of RPE1 cells were treated with indicated doses of Bub1 inhibitors for 3 hr, fixed and analyzed by IFM. Scale bar represents 5 µm. (****G****) Dot plot showing the quantitative results of the experiment shown in (**F**). Sgo2 levels at centromeres and chromosome arms were determined in metaphase cells (n = 150 centromere/arm regions from 15 different cells). Bars represent mean values.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.007](10.7554/eLife.12187.007)10.7554/eLife.12187.008Figure 3---figure supplement 1.Inhibition of Bub1 affects chromatid cohesion.(**A, B**) RPE1 cells were synchronized by thymidine block (4 mM) and released for 12 hr in the presence of 3.3 μM nocodazole as well as solvent (control), 3 μM BAY-320 or 7 μM BAY-524. The cells transfected with mock (Gl2) or Bub1 siRNA-oligonucleotides for 48 hr were synchronized and analyzed in parallel. Micrographs show representative chromosome spreads prepared from mitotic cells. Insets show magnifications of chromosomes; this illustrates representative chromatid cohesion states. Data relate to [Figure 3C](#fig3){ref-type="fig"}. Scale bars represent 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.008](10.7554/eLife.12187.008)

Bub1 inhibition affects CPC localization {#s2-4}
----------------------------------------

In addition to preserving sister chromatid cohesion, Sgo1 and Sgo2 play important roles in the recruitment of the CPC, comprising Aurora B kinase ([@bib43]; [@bib94]). This prompted us to investigate the impact of Bub1 inhibition on Aurora B localization and activity. Consistent with the marked effects on centromere localization of Sgo1/2, we also observed significant effects of Bub1 inhibition on Aurora B localization. After treatment of HeLa cells with BAY-320 or BAY-524, all CPC subunits examined were partially displaced from centromeres ([Figure 4A and B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). While Bub1 inhibition reduced centromeric levels of Aurora B, Borealin and INCENP by \~50% ([Figure 4A and B](#fig4){ref-type="fig"}, left panels), depletion of Bub1 lowered centromere levels of these CPC components by \~70% ([Figure 4A and B](#fig4){ref-type="fig"}, right panels). We emphasize that, due to a lack of resolution, these experiments do not discriminate between centromere- and KT-associated pools of the CPC.10.7554/eLife.12187.009Figure 4.Bub1 inhibition affects localization and activity of the CPC.(**A, C**) Untreated or siRNA transfected (siBub1, siGl2 for control) HeLa S3 cells were synchronized by thymidine block and released for 10 hr, as indicated (BAY-320 was used at 3 μM, BAY-524 at 7 μM). Cells were fixed and stained for Aurora B, Borealin, INCENP, pS7-CENP-A, pS10-histone H3, MCAK, CREST and DNA (DAPI) and analyzed by IFM. Scale bars represent 10 µm. (**B, D**) Histograms show quantitative results of the experiments described in (**A, C**). Measurements represent centromeric levels except for pS10-histone H3 signals, which was monitored along chromosome arms (n = 40--113 cells per condition). Scale bars represent 10 µm, error bars represent SEM. (**E**) FRET experiments were performed on HeLa Kyoto cells stably expressing chromatin (H2B)- or centromere (CENP-B)-fused FRET reporters for Aurora B activity. Cells were synchronized in mitosis by 6 hr treatment with 3.3 μM nocodazole, before the indicated inhibitors and 20 μM MG132 were added prior to live fluorescence microscopy. Heat-map represents the phosphorylation status of the reporter. Scale bar represents 10 µm. (**F**) Left panel: scatter plot depicts CFP/FRET emission ratios of reporter targeted to chromatin (H2B; n = 23--52 cells per condition). Right panel: scatter plot depicts TFP/FRET emission ratios of reporter targeted to centromeres (CENP-B, n = 16--34 cells per condition). Bars represent mean values; \*\*\*p\<0.001 (from unpaired two-tailed Student's t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.12187.009](10.7554/eLife.12187.009)10.7554/eLife.12187.010Figure 4---figure supplement 1.Bub1 inhibition affects localization and activity of the CPC.(**A, B**) Panels relate to the quantitative data shown in [Figure 4B and D](#fig4){ref-type="fig"}. Scale bars represent 10 µm. (**C**) HeLa Kyoto cells stably expressing the chromatin-targeted Aurora B FRET reporter were transfected with control (Gl2) or Bub1 siRNA oligonucleotides for 48 hr and synchronized by 6 hr treatment with 3.3 μM nocodazole, before 20 μM MG132 were added prior to live fluorescence microscopy. Top panel: heat-map represents the phosphorylation status of the reporter. Scale bar represents 10 μm. Bottom panel: dot plot shows measured CFP/FRET emission ratios (n = 14--19 cells per condition). Bars represent mean values; \*\*\*p \< 0.001 (from unpaired two-tailed Student's t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.010](10.7554/eLife.12187.010)

To examine the impact of Bub1 inhibition on the catalytic activity of Aurora B at both centromeres and chromosome arms, we next monitored phosphorylation of CENP-A Ser7 ([@bib108]) and histone H3 Ser10 ([@bib30]; [@bib33]), respectively. Compared to control cells, both Bub1 inhibition and depletion reduced CENP-A and histone H3 phosphorylation by \~50% and \~10--20%, respectively ([Figure 4C and D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), suggesting that interference with Bub1 primarily affects Aurora B activity at centromeres. This conclusion was corroborated by showing that both inhibition and depletion of Bub1 reduced the centromere association of the Aurora B effector protein MCAK ([@bib1]) by \~50% ([Figure 4C and D](#fig4){ref-type="fig"}). Furthermore, use of biosensors for Aurora B activity ([@bib25]) revealed a reduction in fluorescence resonance energy transfer (FRET) ratios for sensors tethered to either chromosome arms (through fusion to H2B) or centromeres (through fusion to histone CENP-B) ([Figure 4E and F](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Collectively, these observations demonstrate that Bub1-dependent phosphorylation plays a major role in the regulation of Aurora B localization and activity. However, neither Bub1 inhibition nor Bub1 depletion resulted in complete removal of Aurora B from centromeres, prompting us to examine the relative contributions of Bub1 and Haspin to the process of CPC recruitment.

Bub1 and Haspin cooperate to recruit CPC to centromeres {#s2-5}
-------------------------------------------------------

While inhibition of Bub1 by BAY-320 or BAY-524 or inhibition of Haspin by 5-Iodotubercidin ([@bib16]) similarly reduced centromere levels of the CPC components Aurora B, Borealin and INCENP to \~40%, combined inhibition of both kinases resulted in a \~80% reduction in CPC levels at centromeres ([Figure 5A and B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). As an important control, treatment of cells with only BAY-320 or BAY-524 did not detectably affect the phosphorylation of the Haspin substrate histone H3 (T3), attesting to the specificity of the two Bub1 inhibitors ([Figure 5A and B](#fig5){ref-type="fig"}).10.7554/eLife.12187.011Figure 5.Bub1 and Haspin inhibition exert additive effect on centromere association of CPC.(**A**) HeLa S3 cells were released from a thymidine block into 3.3 µM nocodazole, before they were additionally treated for 2 hr with the proteasomal inhibitor MG132 and indicated kinase inhibitors. The Haspin inhibitor 5-iodotubercidin (5-ITu \[[@bib16]\]) was used at a concentration of 2.5 µM, BAY-320 at 3 μM and BAY-524 at 7 μM. Cells were fixed, stained for pT3-H3, Aurora B, Borealin, INCENP, CREST and DNA (DAPI) and analyzed by IFM. Anti-pT3-H3 antibody was used to monitor Haspin and Bub1 inhibition, respectively. Scale bar represents 10 µm. (**B**) Histograms show average centromeric (AurB, Borealin, INCENP) or chromosome arm (pT3-H3) signal intensities observed in the experiments shown in (**A**); n = 20--100 cells per condition. Error bars represent SEM, \*\*\*p \< 0.001 (from unpaired two-tailed Student's t-test). (**C**) RPE1 cells expressing endogenously EGFP-tagged Aurora B were incubated with the indicated drugs for several hours before EGFP signals were recorded by live fluorescence imaging. Scale bar represents 5 µm. (**D**) Scatter plots depict Aurora B-EGFP signal intensities at centromeres or arms after treatment with indicated drugs (n = 84--185 centromeres/arm regions from 5--6 cells per condition). Bars represent mean values. For comparison, dashed lines mark the mean values of Aurora B-EGFP signal intensities at arms and centromeres in control cells. Measurements relate to the experiment shown in (**C**).**DOI:** [http://dx.doi.org/10.7554/eLife.12187.011](10.7554/eLife.12187.011)10.7554/eLife.12187.012Figure 5---figure supplement 1.Bub1 and Haspin inhibition exert additive effect on centromere association of CPC.(**A**) Panels relate to the quantitative data shown in [Figure 5B](#fig5){ref-type="fig"}. Scale bars represent 5 µm. (**B**) Asynchronous cultures of RPE1 cells expressing endogenously EGFP-tagged Aurora B were treated with indicated doses of Bub1 inhibitors for 3 hr, fixed and analyzed by IFM. Scale bar represents 5 µm. (**C**) Dot plots show the quantitative results of the experiment shown in (**C**). EGFP-Aurora B and Sgo2 levels at centromeres and chromosome arms were determined in metaphase cells (n = 100 centromeres or arm regions from 10 different cells). Bars represent mean values.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.012](10.7554/eLife.12187.012)

To quantify CPC localization over chromosome arms, analysis of fixed cells proved inadequate. We therefore used an RPE1 cell line expressing one endogenous allele of Aurora B tagged with EGFP ([@bib99]) to monitor the subcellular localization of this kinase in living cells. Following Bub1 inhibition, Aurora B-EGFP levels at chromosome arms increased approximately twofold, concomitant with the described reduction of Aurora B at centromeres ([Figure 5C and D](#fig5){ref-type="fig"}) ([@bib6]; [@bib74]). Interestingly, this change in localization showed a strong correlation with the redistribution of Sgo2 ([Figure 5---figure supplement 1B and C](#fig5s1){ref-type="fig"}). In contrast, treatment of cells with the Haspin inhibitor 5-Iodotubercidin did not induce any significant redistribution of Aurora B from centromeres to chromosome arms; instead, inhibition of Haspin caused an overall reduction of EGFP signals at both centromeres and chromosome arms ([Figure 5C and D](#fig5){ref-type="fig"}). Combined inhibition of Bub1 and Haspin displaced Aurora B from both centromeres and chromosome arms ([Figure 5C and D](#fig5){ref-type="fig"}), in line with the analysis of fixed cells described above. Taken together, these data corroborate the notion that Bub1 and Haspin cooperate in the recruitment of CPC to centromeres through phosphorylation of histone H2A-T120 and histone H3-T3, respectively. In addition, they reveal a role for Bub1 kinase activity, but not Haspin, in restricting CPC localization to the centromere.

Considering the role of Aurora B kinase in the regulation of KT-MT interactions and SAC signaling, the above results raised the question of what contributions Bub1 activity might possibly make to chromosome congression and/or the SAC. Although our initial analyses had not revealed a major impact of BAY-320 or BAY-524 on the overall timing of mitotic progression ([Figure 2](#fig2){ref-type="fig"}), we considered the possibility that inhibition of Bub1 might provoke compensatory effects on mitotic timing, notably a delay in congression and a concomitant acceleration of mitotic exit. According to such a scenario, effects on timing might conceivably cancel each other. In support of this possibility, we emphasize that the inhibition of mitotic kinases with pleiotropic functions have previously been shown to provoke opposing phenotypes ([@bib80]; [@bib99]). To explore the possibility of compensatory effects of Bub1 inhibition, we thus carried out more detailed analyses of mitotic progression, notably KT-recruitment of SAC components, SAC signaling and chromosome congression.

Bub1 inhibition produces minor effects on SAC signaling in HeLa or RPE1 cells {#s2-6}
-----------------------------------------------------------------------------

Depletion of Bub1 is known to weaken SAC signaling in human cells ([@bib48]; [@bib65]; [@bib69]). To test the impact of Bub1 catalytic activity on SAC function, we first analyzed KT levels of Mad1, Mad2 and BubR1 in BAY-320 or BAY-524 treated cells. With the possible exception of a very minor effect on BubR1, the localization of none of these SAC proteins was significantly affected by Bub1 inhibition ([Figure 6A and B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). In sharp contrast, and in agreement with previous reports ([@bib6]; [@bib40]; [@bib68]; [@bib82]), Bub1 depletion decreased KT recruitment of all three proteins by 80--90% ([Figure 6A and B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Thus, the recruitment of several SAC components to KTs strongly depends on Bub1 protein, but not Bub1 kinase activity.10.7554/eLife.12187.013Figure 6.Bub1 inhibition marginally affects SAC signaling.(**A**) Inhibition of Bub1 kinase does not significantly affect recruitment of SAC effectors to unattached KTs. HeLa S3 cells were synchronized by thymidine block and released for 10 hr in the presence of solvent (control), 3 μM BAY-320 or 7 μM BAY-524. Cells transfected with mock (Gl2) or Bub1 siRNA-oligonucleotides for 48 hr were synchronized and analyzed in parallel. The cells were fixed and stained for Bub1, Mad1, closed Mad2 (C-Mad2), CREST and DNA (DAPI) and analyzed by IFM. (**B**) Histogram shows average KT levels of indicated proteins (n = 20--50 cells per condition) observed in the experiment shown in (**A**). Error bars represent SEM. (**C**) RPE1 cells expressing endogenously tagged Bub1-EGFP were synchronized in mitosis by overnight treatment with the Eg5 inhibitor STLC (10 μM) and subsequently treated with 3.3 µM nocodazole and 20 μM MG132 as well as solvent (control), 10 μM BAY-320 or 10 μM BAY-524. Bub1-EGFP KT levels were recorded by 1 sec time-lapse microscopy. After 5 sec, a single KT pair was bleached and fluorescence recovery was monitored. Traces illustrate average fluorescence recovery at KT pairs (n = 10--16 KT pairs per condition); shaded areas represent standard deviation (SD). Half-times and plateaus were determined by non-linear curve fitting based on a one-phase association. (**D, E**) Asynchronously growing cultures of HeLa S3 (**D**) or RPE1 (**E**) cells stably expressing GFP-tagged histone H2B were either directly treated with 3.3 µM nocodazole and the kinase inhibitors BAY-320 (3 μM) and BAY-524 (7 μM) or transfected with control (Gl2) or Bub1 siRNA for 48 hr prior to addition of nocodazole. Cell fates (continued arrest, apoptosis or slippage) and duration of mitotic arrest were determined by fluorescence time-lapse imaging (n = 150 cells per condition, accumulated from 3 independent experiments). Frequencies of observed cell fates as well as average times of arrest are indicated. (**F**) Asynchronously growing HeLa S3 cells or HeLa cells stably expressing GFP-tagged histone H2B were treated with 3.3 µM nocodazole and 0.5 µM of the Mps1 inhibitor Reversine as well as solvent (control), 3 and 10 μM BAY-320, 7 and 10 μM BAY-524 or 2.5 µM of the Aurora B inhibitor ZM-447439 (ZM) (left panel). Alternatively, cells were transfected with control (Gl2) or Bub1 siRNA oligonucleotides for 48 hr prior to addition of 3.3 μM nocodazole and 0.5 µM Reversine (right panel). The cells were monitored by fluorescence time-lapse microscopy and the time elapsed from nuclear envelope breakdown to SAC override and mitotic slippage was determined. Traces illustrate the cumulative frequency of mitotic duration before slippage (n = 50 cells per condition). (**G**) Asynchronously growing RPE1 cells stably expressing GFP-tagged histone H2B were treated and analyzed as described in (**F**). Scale bars represent 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.013](10.7554/eLife.12187.013)10.7554/eLife.12187.014Figure 6---figure supplement 1.Panels relate to the quantitative data shown in [Figure 6D](#fig6){ref-type="fig"}.Scale bars represent 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.014](10.7554/eLife.12187.014)10.7554/eLife.12187.015Figure 6---figure supplement 2.Tagging strategy and IFM analysis of Bub1 KT levels.(**A**) Schematic illustrating the targeting strategy used to introduce the EGFP open-reading frame into the indicated locus of RPE1 cells. The EGFP open reading frame was fused to the 3' exon of one allele of the *BUB1L* gene. (**B**) HeLa cells were synchronized by thymidine block and released for 10 hr in the presence of solvent (control), 3 μM BAY-320 or 7 μM BAY-524. Cells were fixed and stained for Bub1, CREST and DNA (DAPI) and analyzed by IFM. Scale bar represents 10 µm. (**C**) Histogram shows average Bub1 KT levels as measured in the experiment shown in (**B**); n = 20--22 cells per condition.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.015](10.7554/eLife.12187.015)

The association of Bub1 with unattached KTs is dynamic ([@bib32]), raising the question of how Bub1 turnover at KTs is regulated. In the case of the SAC kinase Mps1, autophosphorylation constitutes a major mechanism for controlling Mps1 levels at KTs ([@bib29]; [@bib38]; [@bib99]), and a recent study suggests that Bub1 turnover at KTs is also regulated by autophosphorylation ([@bib2]). To determine whether Bub1 dynamics at KTs is affected by inhibition of Bub1 activity, we made use of an RPE1 cell line harboring one allele of Bub1 tagged by EGFP at the endogenous locus ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). After the treatment of cells with nocodazole to assure complete MT depolymerization and full SAC activation ([@bib80]; [@bib105]), Bub1 levels and turnover at KTs were measured by immunofluorescence microscopy and fluorescence recovery after photobleaching (FRAP), respectively. In comparison to control cells, neither BAY-320 nor BAY-524 detectably affected steady-state Bub1 levels at KTs ([Figure 6---figure supplement 2B and C](#fig6s2){ref-type="fig"}), in line with a recent report ([@bib58]). More importantly, FRAP experiments revealed only minor effects of Bub1 inhibition on Bub1 dynamics at KTs ([Figure 6C](#fig6){ref-type="fig"}). The extent of fluorescence recovery after FRAP was not significantly different in control cells and inhibitor treated cells, revealing an immobile fraction of \~42%, in excellent agreement with previous data ([@bib2]; [@bib32]). The half-time of Bub1 recovery at KTs after FRAP was \~18 sec in controls, again in good agreement with previous data ([@bib2]; [@bib32]). However, whereas Asghar and colleagues observed a \~50% reduction in the half-time of recovery of an exogenously expressed, catalytically inactive EGFP-Bub1 mutant, we found that recovery of endogenously tagged wild-type EGFP-Bub1 was only marginally accelerated by Bub1 inhibition (half-time reduced from 18 s to 12--15 s) ([Figure 6C](#fig6){ref-type="fig"}). When considering this discrepancy, it is important to bear in mind that our data reflect turnover of chemically inhibited wild-type Bub1 expressed at endogenous levels, whereas Ashghar and colleagues monitored mutant versions of overexpressed Bub1, raising the possibility that their results may have been influenced by expression levels and/or mutation-induced structural alterations. We conclude that the effects of Bub1 activity on Bub1 turnover at KTs are at most minor, particularly when compared to the striking effects of Mps1 activity on Mps1 dynamics at KTs ([@bib29]; [@bib38]; [@bib99]).

As a further read-out for the effects of Bub1 inhibition on SAC activity, we used live cell imaging to monitor the responses of nocodazole-arrested HeLa and RPE1 cells to BAY-320 or BAY-524 and compared these to the responses seen in Bub1-depleted cells ([Figure 6D and E](#fig6){ref-type="fig"}). Over a 24 hr observation period, the percentage of HeLa cells maintaining a SAC arrest dropped from 17% in controls to 4% and 2% in response to Bub1 inhibition by BAY-320 and BAY-524, respectively ([Figure 6D](#fig6){ref-type="fig"}, left panel). These shifts in cell fates were largely compensated by increases in the percentages of cells undergoing apoptosis, from 74% in controls to 94% in Bub1-inhibited cells. In contrast, although the duration of mitosis was slightly reduced upon Bub1 inhibition, the extent of mitotic slippage remained at less than 10% under all conditions. In RPE1 cells, maintenance of SAC arrest over 24 hr was more pronounced, but again the percentage of arrested cells dropped from 61% in controls to 51%/44% in response to Bub1-inhibition, with increasing proportions of cells undergoing apoptosis or mitotic slippage ([Figure 6E](#fig6){ref-type="fig"}, left panel). For comparison, depletion of Bub1 from either HeLa or RPE1 cells resulted in a 2--3 fold increase in mitotic slippage at the expense of apoptosis, while the proportion of cells sustaining an arrest remained roughly constant ([Figure 6D and E](#fig6){ref-type="fig"}, right panels). Collectively, these results indicate that Bub1 activity contributes to the maintenance of maximal SAC activity, but that Bub1 protein levels are more important, most likely reflecting the observed role of Bub1 in the KT recruitment of SAC components ([Figure 6A](#fig6){ref-type="fig"}).

Importantly, we also compared the requirements for Bub1 activity and Bub1 protein in a cellular background in which SAC activity was partially compromised by the treatment of HeLa or RPE1 cells with a low dose of Reversine, a widely used inhibitor of the SAC kinase Mps1 ([@bib79]). In agreement with the results described above, Bub1 inhibition marginally reduced the time that Reversine-treated cells remained arrested before overriding nocodazole-induced arrest ([Figure 6F and G](#fig6){ref-type="fig"}, left panels). Addition of Aurora B or Plk1 inhibitors, used as positive controls, led to the expected shortening of the duration of mitotic arrest ([Figure 6F and G](#fig6){ref-type="fig"}, left panels) ([@bib81]; [@bib99]). Similarly, Bub1 depletion also caused a drastic shortening of arrest ([Figure 6F and G](#fig6){ref-type="fig"}, right panels). Taken together with previous studies ([@bib48]; [@bib70]; [@bib69]; [@bib74]), these observations demonstrate that the scaffolding function of Bub1 is required for the SAC, but its catalytic activity is largely dispensable.

Bub1 inhibition does not significantly impair chromosome congression {#s2-7}
--------------------------------------------------------------------

To analyze the impact of Bub1 inhibition on chromosome alignment, we treated cells with the Eg5 inhibitor Monastrol ([@bib42]) and then monitored the restoration of KT-MT attachments during spindle bipolarization in response to drug washout ([Figure 7A and B](#fig7){ref-type="fig"}). While nearly 28% of Bub1-depleted cells failed to completely align all chromosomes, more than 90% of Bub1-inhibited cells showed complete alignment that was indistinguishable from control cells. Inhibition of Aurora B, analyzed for control, resulted in the expected impairment of alignment ([Figure 7A and B](#fig7){ref-type="fig"}). To complement these assays, we also used immunofluorescence microscopy to quantify the frequency of micronucleation, a read-out for chromosome segregation errors, in HeLa and RPE1 cells. While partial inhibition of Aurora B kinase provoked an increase in micronucleation in both cell lines, as expected ([@bib27]; [@bib91]), Bub1 inhibition only marginally increased the frequency of micronucleation ([Figure 7C](#fig7){ref-type="fig"}). This result supports the view that Bub1 inhibition causes surprisingly mild defects in chromosome congression or segregation ([Figure 2](#fig2){ref-type="fig"} and [7A](#fig7){ref-type="fig"}). Further corroborating this conclusion, we found that BAY-320 or BAY-524 treatment exerted no significant effects on the kinetochore recruitment of the motor protein CENP-E ([Figure 7D and E](#fig7){ref-type="fig"}, left panels). In contrast, Bub1 depletion reduced CENP-E levels at KTs by \~40% ([Figure 7D and E](#fig7){ref-type="fig"}, right panels), in agreement with previous reports ([@bib40]; [@bib82]). Taken together, these results show that Bub1 kinase activity is largely dispensable for chromosome congression and segregation. It follows that even though Bub1 inhibition results in a marked reduction of Aurora B levels at centromeres ([Figure 4](#fig4){ref-type="fig"}), these levels are still sufficient to ensure largely faithful chromosome segregation. Conversely, Bub1 protein is clearly important for efficient chromosome congression, presumably reflecting the role of Bub1 in CENP-E recruitment to KTs.10.7554/eLife.12187.016Figure 7.Bub1 inhibition does not significantly affect chromosome congression.(**A**) HeLa S3 cells were transfected with control (Gl2) or Bub1 siRNA-oligonucleotides for 48 hr, synchronized by thymidine block and released for 12 hr in the presence of the Eg5 inhibitor monastrol to induce the formation of monopolar spindles. The capacity of spindle bipolarization and metaphase plate formation was tested by monastrol wash-out and addition of MG132 and indicated drugs for 2 hr (n = 170--200 cells). Percentages indicate the frequencies of depicted spindle morphologies. (**B**) Histograms show the frequencies of full, partial (≤5 unaligned chromosomes) or failed metaphase chromosome alignments that were observed in the experiment shown in (**A**). (**C**) HeLa S3 and RPE1 cells were treated for 16 hr with the indicated drugs, fixed and analyzed by IFM. Histograms show the frequency of micronucleation among interphase cells (n = 300 cells per condition). (**D**) Depletion but not inhibition of Bub1 kinase affects recruitment of CENP-E to unattached kinetochores. Untreated HeLa S3 cells or cells transfected with control (Gl2) or Bub1 siRNA-oligonucleotides (for 48 hr) were synchronized by thymidine block and released for 10 hr in the presence or absence of 3 μM BAY-320 or 7 μM BAY-524. The cells were fixed and stained for CENP-E, CREST, DNA (DAPI) and analyzed by IFM. (**E**) Histograms show average CENP-E KT levels observed in prometaphase cells. Data relate to micrographs shown in (**D**). Error bars represent SEM. Scale bars represent 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.12187.016](10.7554/eLife.12187.016)

Bub1 inhibition sensitizes HeLa cells to clinically relevant doses of Paclitaxel {#s2-8}
--------------------------------------------------------------------------------

Interference with the SAC proteins Mps1 or BubR1 was previously shown to exert synergistic effects with Paclitaxel treatment of tumor cells, significantly elevating the frequency of chromosome missegregation and lethality ([@bib36]; [@bib55]). Thus, we asked how inhibition of Bub1 kinase activity by BAY-320 or BAY-524 would impact on cells in which MT dynamics was compromised by low doses of Paclitaxel. Importantly, when used at clinically relevant doses of 1--4 nM, Paclitaxel induces spindle defects and aneuploidy without delaying mitotic progression ([@bib7]; [@bib11]; [@bib34]; [@bib36]). While single treatment with 1--4 nM Paclitaxel produced modest impairment of cell proliferation, the concomitant application of the Bub1 inhibitors, BAY-320 at 3 μM or BAY-524 at 7 or 10 μM, clearly exacerbated inhibition of proliferation. Effects were particularly drastic in aneuploid HeLa cells ([Figure 8A and B](#fig8){ref-type="fig"}, top panels), while diploid RPE1 cells were less affected ([Figure 8A and B](#fig8){ref-type="fig"}, bottom panels). For comparison, we also examined the effects of combining low dose Paclitaxel treatment with partial inhibition of Mps1 by Reversine ([@bib36]). This analysis shows that the combination of Paclitaxel with either Mps1 or Bub1 inhibition produced similar synergistic effects, albeit with cell-type specific differences ([Figure 8A and B](#fig8){ref-type="fig"}). Using extensive dose-response analyses, synergy between BAY-320 and Paclitaxel treatment was further confirmed for both HeLa ([Figure 8C](#fig8){ref-type="fig"}) and non-small cell lung cancer cells ([Figure 8D](#fig8){ref-type="fig"}). In future, it will be interesting to determine to what extent combined treatments differentially affect aneuploid *versus* diploid cells ([@bib36]; [@bib50]; [@bib62]).10.7554/eLife.12187.017Figure 8.BAY-320 and BAY-524 treatment sensitizes cells to low doses of Paclitaxel.(**A**) Micrographs show colony formation of HeLa (top panel) and RPE1 cells (bottom panel) treated for 7 days with solvent (control) or the indicated kinase inhibitors in the presence or absence of 4 nM Paclitaxel. (**B**) Histograms quantify colony formation in HeLa (top panels) and RPE1 cells (bottom panels) treated with the indicated kinase inhibitors in the presence or absence of 1--4 nM Paclitaxel for 7 days. (**C, D**) IC~50~-Isobolograms confirm the synergistic effect of BAY-320 and Paclitaxel on cell survival. HeLa cells (**C**) or NCI-H1299 non-small cell lung cancer cells (**D**) were grown in the presence various concentrations of BAY-320 (0.1--10 μM) and paclitaxel (1--100 nM) in mono (Z1, Z11) and in nine different fixed-ratio combinations (Z2-Z10). IC~50~ values were determined and the respective BAY-320 and Paclitaxel concentrations plotted in IC~50~ Isobolograms (left panel). The grey dashed lines indicate the results expected for additivity. Combination indices (CIs) were calculated according to the median-effect model of Chou-Talalay ([@bib13]) and plotted over fixed-ratio combinations Z2-Z10 (right panel). The red dashed line indicates a CI of 0.8 (defined as upper limit for a synergistic interaction). (**E**) Time-lapse stills of HeLa cells expressing H2B-GFP illustrate chromosome segregation defects that were used to classify cell fates in the experiments described in (**F**); arrowheads point to chromosome bridges and lagging chromosomes. (**F**) HeLa (top panels) and RPE1 cells (bottom panels) stably expressing H2B-GFP were treated with solvent (control) or the indicated kinase inhibitors in the presence or absence of 1--4 nM Paclitaxel and monitored by fluorescence time-lapse imaging. Histograms show the frequencies of chromosome segregation defects, following the classification illustrated in (**E**) (n = 100 cells per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.12187.017](10.7554/eLife.12187.017)

To assess whether the observed impairment of proliferation results from errors in chromosome segregation ([@bib50]), we scored HeLa and RPE1 cells expressing GFP-H2B for mild and severe chromosomal defects, as illustrated in [Figure 8E](#fig8){ref-type="fig"}. Following application of the above Paclitaxel and Bub1/Mps1 inhibitor treatments, the frequencies of chromosomal defects were monitored by fluorescence time-lapse imaging and quantified ([Figure 8F](#fig8){ref-type="fig"}). Consistent with the micronucleation data described above ([Figure 7](#fig7){ref-type="fig"}), Bub1 inhibition alone did not significantly elevate the frequency of chromosome missegregation in either HeLa or RPE1 cells ([Figure 8F](#fig8){ref-type="fig"}). For comparison, interference with the SAC by inhibition of Mps1 led to a marked increase in segregation defects in both cell lines, as expected ([Figure 8F](#fig8){ref-type="fig"}). Most importantly, HeLa cells displayed an even higher frequency of severe chromosome segregation defects when Bub1 inhibition was combined with 1--4 nM Paclitaxel, comparable to the consequences of combined Mps1 inhibition and Paclitaxel treatment ([Figure 8F](#fig8){ref-type="fig"}). In contrast, Bub1 inhibition only marginally elevated the rate of Paclitaxel-induced chromosome missegregation in RPE1 cells, while combinatorial treatment with Reversine still resulted in a high rate of mild segregation defects. Considering the strong correlation in the data shown in [Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}, it is tempting to conclude that chromosome segregation errors constitute the most likely cause for the observed impairment of cell proliferation when Bub1 inhibition is combined with low dose Paclitaxel treatment. Thus, although inhibition of Bub1 kinase activity per se exerts only minor effects on SAC functionality, chromosome segregation and mitotic progression, treatment with BAY-320 or BAY-524 sensitizes cells to low, clinically relevant doses of Paclitaxel. These findings are clearly relevant for the potential therapeutic use of Bub1 inhibitors.

Discussion {#s3}
==========

Bub1 kinase is important for chromosome congression and the fidelity of chromosome segregation in species from yeast to vertebrates (reviewed in \[[@bib21]; [@bib26]\]). However, the role of the catalytic activity of Bub1 in different species remained a matter of debate. Here, we have characterized two novel small molecule inhibitors of Bub1, BAY-320 and BAY-524, and used these reagents to explore the role of Bub1 catalytic activity in mitotic processes. A systematic comparison of the phenotypic consequences of Bub1 inhibition with those of siRNA-mediated Bub1 depletion leads us to conclude that Bub1 functions primarily as a scaffolding protein. However, we see prominent effects of Bub1 kinase inhibition on chromosome arm cohesion and CPC localization and subtle effects on mitotic progression, including the efficacy of the SAC. Finally, we demonstrate a striking synergy between inhibition of Bub1 activity and Paclitaxel-induced interference with MT dynamics, which manifests itself in a marked increase in chromosome segregation errors and drastically reduced cell proliferation. Our results contribute to clarify the role of Bub1 kinase activity in different mitotic processes. Moreover, they have important implications for potential use of Bub1 inhibitors in therapeutic applications.

Validation of BAY-320 and BAY-524 as Bub1 inhibitors {#s3-1}
----------------------------------------------------

Clarification of the role of Bub1 activity in mitosis has previously been hampered by the absence of specific inhibitors. While genetic or siRNA-mediated depletion experiments generally suffer from poor temporal resolution, small molecule inhibitors offer a unique opportunity for acute kinase inactivation. The only previously described inhibitor of Bub1 is the bulky ATP analog 2OH-BNPP1 ([@bib41]; [@bib51]; [@bib58]; [@bib67]), but neither the specificity nor the efficacy of this compound in intact cells have been thoroughly characterized. Here, we document that both BAY-320 and BAY-524 effectively inhibit Bub1 kinase activity, in intact cells as well as in vitro. In addition to inhibiting phosphorylation of histone H2A-T120, both compounds cause a persistence of chromosome arm cohesion, validating their efficacy ([@bib44]; [@bib58]). Moreover, in vitro assays performed on a large panel of kinases showed that inhibition of off-target substrates required at least 20x higher concentrations of BAY-320 than inhibition of Bub1, and for one potentially relevant off-target, the kinase Haspin, we show that intracellular phosphorylation of a major substrate of this kinase is not decreased by inhibitor concentrations that effectively inhibit Bub1. Furthermore, a binding assay performed on a panel of 403 human kinases documents exquisite selectivity of BAY-320 for Bub1. Thus, we are confident that these new Bub1 inhibitors constitute highly effective and specific tools to explore the role of Bub1 kinase activity.

Impact of Bub1 inhibition on mitotic progression {#s3-2}
------------------------------------------------

The major conclusion emerging from the present study is that the overall impact of Bub1 inhibition on mitotic progression is surprisingly mild, clearly less severe than the impact of Bub1 depletion. This reinforces the notion that the requirement for Bub1 during chromosome congression and segregation primarily reflects a scaffolding function ([@bib23]; [@bib48]; [@bib71]; [@bib76]; [@bib82]). It is difficult to exclude that a small fraction of total Bub1 kinase activity might be refractory to inhibition and suffice for functionality, but we emphasize that genetic elimination of Bub1 kinase activity is compatible with mouse development, arguing similarly against an essential role of Bub1 kinase activity for mitotic progression ([@bib74]). Thus, inhibitor studies and genetic data concur to indicate that lack of Bub1 kinase activity produces only mild disturbances of mitotic progression.

We show that Bub1 inhibition by BAY-320 or BAY-524 results in loss of Shugoshin and CPC subunits proteins from centromeres/KTs, and that CPC levels at these locations are further reduced upon simultaneous inhibition of Bub1 and Haspin, in line with the established roles of these kinases in the phosphorylation of histones H2A-T120 and H3-T3, respectively ([@bib101]; [@bib102]). Furthermore, both Sgo2 and Aurora B relocalize to chromosome arms when Bub1 is inhibited. Phosphorylation of Sgo2 by Aurora B promotes Sgo2 interaction with phosphatase 2A (PP2A) ([@bib88]), and PP2A in turn protects cohesin proteins against phosphorylation ([@bib47]; [@bib75]). Thus, colocalization of Sgo2 and Aurora B in Bub1-inhibited cells provides a straightforward explanation for the observed persistence of arm cohesion ([@bib46]; [@bib69]). However, alternative mechanisms should not be excluded and it might be rewarding to explore a possible connection between Bub1 kinase and the Sororin-Wapl pathway ([@bib72]).

It may appear surprising that the persistent chromosome arm cohesion observed in Bub1 inhibited cells did not markedly prolong mitotic timing ([Figure 2](#fig2){ref-type="fig"}). However, we note that depletion of Wapl also causes persistent cohesion without significantly affecting mitotic progression ([@bib53]). In contrast to Bub1 inhibition, depletion of Bub1 markedly extended mitotic timing ([Figure 2](#fig2){ref-type="fig"}). One straightforward explanation for this observation is that Bub1 depletion, but not Bub1 inhibition, caused the displacement of CENP-E from KTs, a motor protein required for efficient chromosome congression ([@bib3]; [@bib73]; [@bib90]). A mechanism centered on CENP-E may also explain the observation that Bub1 depletion exerted a more extensive mitotic delay in the hypertriploid HeLa cells than in diploid RPE1 cells. Considering the important role of Aurora B in the regulation of KT-MT interactions ([@bib9]; [@bib26]), it is remarkable that the observed reduction of centromere/KT-associated CPC caused by Bub1 inhibition did not exert a more profound effect on the fidelity of chromosome segregation. This suggests that approximately half the normal centromere/KT levels of CPC are sufficient to confer functionality. In line with this conclusion, we note that partial impairment of CPC recruitment to centromeres/KTs did not abolish viability or trigger extensive defects in chromosome segregation in budding yeast or chicken DT40 cells ([@bib8]; [@bib107]).

Inhibition of Bub1 kinase activity did not significantly reduce the KT recruitment of Mad1, Mad2 and BubR1 and barely affected the ability of nocodazole-treated cells to maintain a SAC arrest. Even when SAC activity was compromised by partial inhibition of the SAC kinase Mps1, Bub1 inhibition triggered only minor weakening of SAC signaling. In striking contrast, Bub1 depletion produced a drastic weakening of the SAC in this sensitized background. For comparison, combined inhibition of Mps1 and either Plk1 or Aurora B resulted in a complete SAC shutdown and immediate mitotic exit, in line with previous results ([@bib81]; [@bib99]). Collectively these findings confirm that mitotic functions of Bub1 depend primarily on Bub1 protein rather than kinase activity. In future, it will be interesting to explore whether Bub1 activity contributes to purported non-mitotic functions of Bub1 ([@bib67]; [@bib106]).

Use of Bub1 inhibitors for therapeutic applications {#s3-3}
---------------------------------------------------

Inhibition of SAC kinases has emerged as a potentially attractive strategy to kill tumor cells ([@bib36]; [@bib78]). Several inhibitors of the SAC kinase Mps1 were shown to exert anti-tumor effects in mouse models ([@bib15]; [@bib52]; [@bib89]; [@bib92]), but toxicity associated with single agent therapy remains a concern ([@bib63]). Instead, combination of anti-SAC compounds with MT-targeting agents may constitute a more rewarding strategy ([@bib39]; [@bib62]). Our present data suggest that it may be attractive to use inhibitors of Bub1 in combinatorial therapy. While BAY-320 and BAY-524 had comparatively little effect on mitotic progression when used as single agents, they showed extensive anti-proliferative activity, accompanied by strong increases in chromosome segregation errors, when combined with therapeutic doses of Paclitaxel. A plausible explanation for this synergy is that Paclitaxel increases KT-MT attachment errors to levels that can no longer be corrected when Aurora B/CPC is partially displaced upon Bub1 inhibition. Interestingly, these synergistic effects were substantially more pronounced in aneuploid HeLa cells than in near-diploid RPE1 cells, suggesting a potential therapeutic window. These findings clearly encourage further exploration of the potential use of Bub1 inhibitors for therapeutic applications.

Materials and methods {#s4}
=====================

Preparation of BAY-320 and BAY-524 inhibitors {#s4-1}
---------------------------------------------

BAY-320 and BAY-524 were synthesized as described previously ([@bib31]). For biochemical and cellular experiments BAY-320 and BAY-524 were used from stock solutions in dimethyl sulfoxide (DMSO). Working concentration of Bub1 inhibitors are indicated in Figures and Figure legends, respectively.

Determination of IC~50~-concentrations {#s4-2}
--------------------------------------

Inhibitory activities BAY-320 and BAY-524 towards Bub1 in presence of 2 mM ATP were quantified as previously published ([@bib31]). A time-resolved fluorescence energy transfer (TR-FRET) kinase assay was used to measure phosphorylation of the synthetic peptide Biotin-Ahx-VLLPKKSFAEPG (C-terminus in amide form, Biosyntan, Berlin, Germany) by the recombinant catalytic domain of human Bub1 (amino acids 704--1085). Recombinant human Bub1 (704--1085) was expressed in Hi5 insect cells with an N-terminal His6-tag and purified by affinity- (Ni-NTA) and size exclusion chromatography.

Kinase selectivity profiling {#s4-3}
----------------------------

BAY-320 was screenedin vitro, at 10 µM and 10 µM ATP, against a panel of 222 kinases using the Eurofins kinase profiler screen (Millipore). In addition, BAY-320 was screened, at 300 and 1000 nM, in an active site-directed competition-binding assay measuring 403 human kinases (Lead Hunter, DiscoverX Kinome Scan).

In vitro kinase assay {#s4-4}
---------------------

HEK 293T cells were transfected with plasmids coding for LAP-tagged Bub1 wild-type (WT) or the K821R kinase-dead (KD) mutant (kindly provided by G. Kops, Utrecht, Netherlands) ([@bib85]). After induction of mitotic arrest (18 hr incubation with 1 μg/ml of nocodazole), the cells were harvested and lysed in kinase lysis buffer (50 mM HEPES pH7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM Na~3~VO~4~, 1 mM β-glycerophosphate, 1 mM NaF and complete protease inhibitor (Roche)). Lysates were cleared by centrifugation for 15 min at 21,000 *g*, 4°C, and LAP-Bub1 proteins isolated by a 2 hr incubation with S-protein-agarose (Novagen, EMD Chemical, CA, USA). Beads were washed six times in lysis buffer containing increasing concentrations of NaCl (150 mM, 200 mM, 300 mM, 400 mM, 500 mM and 600 mM) and three times in kinase buffer (20 mM HEPES pH7.5, 100 mM KCl, 10 mM MgCl, 1 mM Na3VO4, 1 mM -glycerophosphate, 1 mM NaF, 1 mM DTT). The bead-bound LAP-Bub1 was then aliquoted and used for kinase assays in 30-μl reaction volumes. Kinase reactions were carried out at 30°C in kinase buffer in the presence of 100 μM ATP, 5 μCi γ-^32^P-ATP, 1 μg recombinant histone H2A (NEB, Frankfurt am Main, Germany) as substrate, and serial dilutions of Bub1 inhibitors. The reactions were stopped after 30 min by the addition of sample buffer and heating to 95°C. The samples were then resolved by SDS-PAGE and visualized by autoradiography and Western blotting.

Cell culture {#s4-5}
------------

HeLa S3 cells, HeLa S3 cells expressing histone H2B-GFP ([@bib84]), HeLa Kyoto cells expressing a FRET reporter for Aurora B fused to histone H2B ([@bib96]) and HEK293T cells were grown under standard conditions in DMEM-Glutamax medium (Invitrogen, CA, USA), supplemented with 10% heat-inactivated fetal calf serum (FCS) (PAN Biotech, Aidenbach, Germany) and penicillin-streptomycin (Pen-Strep; 100 IU/ml and 100 mg/ml respectively, Gibco Life Technologies, Zug, Switzerland). hTERT-RPE1 cells and hTERT-RPE1 cells expressing histone H2B-GFP (kind gift of Stephen Taylor, University of Manchester, UK) were cultured in F12 DMEM nutrient mixture F-12 HAM (Sigma Aldrich, MO, USA) supplemented with 10% heat-inactivated FCS, L-glutamine (2 mM; PAN Biotech, Aidenbach, Germany), sodium bicarbonate (0.35%; Sigma-Aldrich, MO, USA) and Pen-Strep. NCI-H1299 cells were grown under standard conditions in RPMI-1640 medium supplemented with L-glutamine (Biochrome, Berlin, Germany) and 10% fetal calf serum (Biochrome, Berlin, Germany). All cell lines were routinely tested for mycoplasma, using PCR (by the lab in Basel) or the MycoAlert Mycoplasma Detection Assay (by the lab in Berlin). HeLa cells (ACC-57) were obtained from the German Collection of Microorganisms and Cell Cultures, Braunschweig, and authentication was done at provider prior to shipment; NCI-H1299 (CRL-5803) were obtained from ATCC and authentication was done by STR profiling (authentication service at German Collection of Microorganisms and Cell Cultures, Braunschweig). Thymidine arrest was performed for 24 hr and cells were either released into fresh medium for 10 hr or into medium supplemented with Nocodazole for 12--14 hr. Thymidine (Sigma-Aldrich) was used at 2 mM if not stated otherwise, Nocodazole (Sigma-Aldrich) at 3.3 μM if not stated otherwise, RO-3306 at 10 μM (Calbiochem, Darmstadt, Germany), Paclitaxel (Calbiochem) at 1--4 nM, Reversine (Enzo Life Sciences, Lausen, Switzerland) at 0.25 and 0.5 μM, ZM-447439 (Tocris Bioscience, \[[@bib18]\]) at 1.25, 2.5 and 5.0 μM, 5-Iodotubercidin (5'Itu, Santa Cruz Biotechnology, TX, US) at 2.5 μM, Monastrol (Enzo Life Sciences) at 150 μM and MG132 (Calbiochem) at 10 and 20 μM.

Transient plasmid transfection and siRNA-mediated protein depletion {#s4-6}
-------------------------------------------------------------------

Transient transfections of HEK293T cells with plasmids and small interfering RNA (siRNA) duplexes were performed using TransIT-LT1 transfection reagent (Mirus Bio, Madison, WI) and Oligofectamine (Invitrogen), respectively, according to manufacturers protocols. The following siRNA duplex oligonucleotides were used: siGl2 CGTACGCGGAATACTTCGA ([@bib20]), siBub1 CCAGGCTGAACCCAGAGAGTT (Tang 2004). All siRNA duplex oligonucleotides were ordered from Qiagen (Hilden, Germany).

Fluorescence-activated cell sorting {#s4-7}
-----------------------------------

HeLa S3 or RPE1 cells were incubated with kinase inhibitors or depleted of the indicated proteins for 48 hr. Cell suspensions were then fixed with 70% ice-cold ethanol and incubated with 0.2 mg/ml RNase (Sigma-Aldrich) and 5 μg/ml propidium iodide (Sigma-Aldrich). Cellular DNA content was determined by flow cytometry using FACSCanto II (BD Biosciences Clontech, San Jose, CA, USA) and FlowJo (Treestar, Ashland, OR, USA) instruments.

Cell extracts and sample preparation for Western blot analysis {#s4-8}
--------------------------------------------------------------

Cells extracts were prepared on ice for 30 min in Tris lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.5% IGEPAL CA-630, 30 μg/ml RNAse, 30 μg/ml DNAse, 1 mM DTT, protease inhibitors cocktail (Roche, Basel, Switzerland) and phosphatase inhibitor cocktails (cocktails 2 and 3, Sigma-Aldrich). Lysates were cleared by centrifugation for 15 min at 21,000 *g*, 4°C, and proteins were resolved by SDS-PAGE and analyzed by Western blotting.

Histone isolation {#s4-9}
-----------------

HeLa S3 cells were as described above and mitotic cells were collected by shake-off. The cells were the washed with cold PBS and lysed at 4°C for 30 min using histone lysis buffer (50 mM Tris pH 7.8, 300 mM NaCl, 1% IGEPAL CA-630). Nuclei were collected by centrifugation (110 *g*, 4°C, 10 min) and washed three times with histone lysis buffer. After an additional wash with Tris-EDTA (100 mM Tris, 1 mM EDTA), the nuclear pellet was incubated for 2 hr in 0.4 M HCl at 4°C. After high-speed centrifugation of the sample, 6 volumes of acetone were added to the supernatant, followed by overnight incubation at -20°C. Histones were collected by centrifugation, washed with acetone, air-dried and resolved by SDS-PAGE.

Antibodies {#s4-10}
----------

Antibodies used for Western blotting: anti-Bub1 (\[[@bib28]\] or ab9000, Abcam, Cambridge, UK), anti-pT120-H2A (Active Motif, Carlsbad, CA, USA) and anti-α-tubulin (DM1A, Sigma-Aldrich). Antibodies used for immunofluorescence microscopy: anti-Mad1 (clone 117--468 \[[@bib22]\]), anti-cMad2 (clone 107--276 \[[@bib22]\]) anti-Borealin ([@bib49]), anti-INCENP (clone 58--217, ab23956, Abcam), anti-Bub1 (antibody against Bub1 hybridoma (clone 62--406) was produced after mice were injected with Bub1 recombinant protein spanning residues 1--318, anti-Bub1 (ab9000, Abcam), CREST anti-human auto-immune serum (Immunovision, Springdale, AR, USA), anti-Aurora B (AIM-1, BD Biosciences, San Jose, CA, USA), anti-Bub1 (ab9000, Abcam), anti-CENP-E (1H12, Abcam), anti-Mad2 (A300-301A, Bethyl Laboratories, Montgomery, TX, USA), anti-Sgo1 (Abnova, Taipei, Taiwan), anti-Sgo2 (Bethyl Laboratories), anti-pT120-H2A (Active Motif, Carlsbad, CA, USA; ABIN482721), anti-pS7CENP-A (clone NL41, Merck Millipore, Billerica, MA, USA), anti-pT3-H3 (clone 9714, Cell Signaling Technology, Danvers, MA, USA) and anti-pS10-H3 (Millipore, Billerica, MA, USA). The polyclonal MCAK (R120) antibody was raised in rabbits by immunization with bacterially expressed His-MCAK~aa588-725~. For immunofluorescence experiments, all primary antibodies were detected with AlexaRed-594-, AlexaRed-564-, and AlexaGreen-488-labeled secondary anti-mouse and anti-rabbit antibodies (Invitrogen, Carlsbad, CA, USA) or Cy5-conjugated donkey antibodies (Dianova, Hamburg, Germany). For Western blotting, signals were detected using HRP-conjugated anti-mouse or anti-rabbit antibodies (Pierce, Rockford, IL, USA).

In-cell western {#s4-11}
---------------

HeLa cells were seeded into 96-well plates for 5 hr at 37°C (ca. 25'000 cells/well). Then, cells were treated with Nocodazole for 16 hr and varying concentrations of test compounds for 1 hr. The cells were fixed, washed and blocked with buffer before incubating with the primary antibody (Phospho-Histone H2A; ABIN482721; 1:200) overnight at 2--8°C. After washing, secondary IRDye-labeled antibody mix with cell stains was added for 1 hr and washed again. Plates were scanned with a LiCor Odyssey Infrared Imager at 800 nm for P-H2A and at 700 nm for Draq5/Sapphire, a cell stain. The signal ratio (800/700 nm) for cells treated only with Nocodazole was set to 100% and the corresponding ratio for untreated cells to 0%. The IC~50~ value was then determined by curve fitting (using a four parameter fit).

Immunofluorescence microscopy, image processing, quantification and live cell imaging {#s4-12}
-------------------------------------------------------------------------------------

For fluorescence microscopy cells were grown on coverslips and fixed in PTEMF buffer (20 mM PIPES, pH 6.8, 0.2% Triton X-100, 10 mM EGTA, 1 mM MgCl~2~, 4% formaldehyde) or methanol at **-**20°C (for CENP-A pS7), respectively. Images of randomly selected cell were acquired as z-stacks using a DeltaVision microscope (GE Healthcare) on an Olympus IX71 base (Applied Precision, WA, USA), equipped with a Plan Apochromat N 60x/NA1.42 oil immersion objective (Olympus) and a CoolSNAP HQ2 camera (Photometrics). Serial optical sections were deconvolved and projected using SoftWorx software (GE Healthcare). Images were quantified as previously described ([@bib99]) using automated pipelines run by Cell Profiler software ([@bib10]). Results from 2--3 independent experiments were pooled and statistical analysis was done with GraphPad Prism software. Error bars on histograms illustrate SEM. Scale bars represent 10 μm.

For time-lapse imaging, cells were imaged using a Nikon ECLIPSE Ti microscope equipped with a CoolLED pE-1 illumination system and a 20x/NA0.75 air Plan Apochromat objective (Nikon) in a climate-controlled environment. Images were acquired at multiple positions at indicated time intervals. MetaMorph 7.7 software (MDS Analytical Technologies, Sunnyvale, CA, USA) was used for acquisition and processing of data. FRET, FRAP, and high sensitivity microscopy (monitoring endogenously EGFP-tagged proteins) experiments were carried out using a spinning disk confocal system (Intelligent Imaging Innovations) based on a Zeiss Axio Observer stand equipped with a Photometric Evolve 512 back-illuminated EMCCD camera, 63x/NA1.4 plan apochromat objective and diode lasers and run by SlideBook software. FRET analyses were carried out by excitation with a 440 nm diode laser and by recording of CFP (CFP signal) and YFP (FRET signal) fluorescence emission in z-stacks. Background-corrected FRET ratios (CFP signal/FRET signal) were calculated in ImageJ using the Ratio Plus plugin. FRAP analysis of EGFP-Bub1 was performed with a 488 diode laser on one KT pair per cell. Overall bleaching was corrected using the signal intensities at a cytoplasmic region not targeted for photobleaching (average of the first 4 frames). Fluorescence recovery half-times and plateaus were determined by non-linear curve fitting based on a one-phase association in Prism software (GraphPad).

Colony formation assay {#s4-13}
----------------------

Asynchronous cell cultures (50,000/well) were plated on 6-well plates (Falcon). After 7 days of proliferation in the presence of the indicated drugs, the cells were fixed with ice-cold methanol at -20°C and stained with 0.1% Cresyl Violet according to standard procedures. Dried culture plates were scanned and intensities measured using ImageJ after black-and-white-conversion and inversion of the images.

IC~50~ isobolograms {#s4-14}
-------------------

BAY-320 plus Paclitaxel combination studies were conducted with HeLa and NCI-H1299 cells. Cells were plated into 384-well plates at 600 (HeLa) or 700 (NCI-H1299) cells per well. After 24 hr, cells were treated with BAY-320 (concentration range, 1E-07 M to 1E-05 M) and Paclitaxel (concentration range, 1E-09 M to 1E-07 M) for single compound treatments, and in nine different fixed-ratio combinations of BAY-320 (D1) and Paclitaxel (D2) (0.9xD1+0.1xD2, 0.8xD1+0.2xD2, 0.7xD1+0.3xD2, 0.6xD1+0.4xD2, 0.5xD1+0.5xD2, 0.4xD1+0.6xD2, 0.3xD1+0.7xD2, 0.2xD1+0.8xD2, 0.1xD1+0.9xD2). Cell viability was assessed after 96 hr exposure, using the Cell Titre-Glo Luminescent Cell Viability Assay (Promega). IC~50~ values were determined by means of a 4-parameter fit after normalization of measurement data to vehicle (DMSO)-treated cells (=100%) and readings taken immediately before compound addition (=0%). IC~50~ isobolograms were plotted with the actual concentrations of the two compounds on the x- and y-axis, and the combination index (CI) was calculated according to the median-effect model of Chou-Talalay ([@bib13]). A CI of ≤0.8 was defined as more than additive (i.e. synergistic) interaction, and a CI of ≥1.2 was defined as antagonistic interaction.

rAAV-mediated gene targeting {#s4-15}
----------------------------

For gene targeting, homology arms to human Bub1 (*BUB1*) gene were amplified from RPE1 cell genomic DNA. Targeting constructs allowing the insertion of an EGFP tag C-terminal to Bub1 were assembled by 4-piece ligation in a *Not*I-digested pAAV vector. Recombinant adenovirus-associated virus (rAAV) particles were generated as previously described ([@bib4]). RPE1 cells were infected with 3 ml of viral supernatant for 48 hr and then expanded into fresh medium for an additional 48 hr. FACS sorting was used to select EGFP-positive cells, as previously described ([@bib14]). To facilitate detection of fluorescence at mitotic stages, cells were synchronized with RO-3306 (10 μM) for 18 hr and released into nocodazole (50 nM) for 2 hr, before they were trypsinized and subjected to sorting in the continued presence of nocodazole (10 nM). Infected or uninfected cells were filtered (30 μm, Partec) and EGFP-positive cells (488 excitation, 514/30 emission filter) were isolated on an Aria IIIu (BD) cell sorter by selecting the 514/30 channel against a 585/42 filter detecting cellular autofluorescence. Single cells were sorted into 96-well plates filled with conditioned medium and positive clones screened for by fluorescence microscopy.

Funding Information
===================

This paper was supported by the following grants:

-   Fellowships for Excellence International PhD Program, Werner von Siemens Foundation Graduate Student Fellowship to Anna Pauline Baron.

-   Swiss National Science Foundation 310030B_149641 to Anna Pauline Baron, Conrad von Schubert, Erich A Nigg.

-   Universität Basel to Anna Pauline Baron, Conrad von Schubert, Erich A Nigg.

We thank the project team at Bayer Pharma AG for their contribution. We also thank Prof. GJPL Kops (University Medical Center Utrecht) and Dr. M Vleugel (University of Technology Delft) for providing the LAP-Bub1 and LAP-Bub1(KD) plasmids, Stephen Taylor (University of Manchester) for the RPE1 H2B-GFP cell line, Zhen Dou (University of Science and Technology of China, Hefei) for the generation of the MCAK antibody and Michael Lampson (University of Pennsylvania) as well as Daniel Gerlich (Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna) for Aurora B biosensor constructs and HeLa Kyoto cell lines. We also thank the Biozentrum's Imaging Core Facility for support (O Biehlmaier, A Loynton-Ferrand and N Ehrenfeuchter) and Janine Zankl (Biozentrum FACS facility) for help with FACS analysis. APB was funded by a fellowship from the 'Fellowships for Excellence' International PhD Program (University of Basel, Switzerland) supported by the Werner von Siemens Foundation. This work was supported by the University of Basel and the Swiss National Science Foundation (310030B_149641).

Additional information {#s5}
======================

The other authors declare that no competing interests exist.

GS: Employee of Bayer Pharma AG.

MH: Employee of Bayer Pharma AG.

AM: Employee of Bayer Pharma AG.

JS: Employee of Bayer Pharma AG.

AFM: Employee of Bayer Pharma AG.

FvN: Employee of Bayer Pharma AG.

DM: Employee of Bayer Pharma AG.

APB, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

CvS, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

FC, Acquisition of data, Analysis and interpretation of data.

GS, Conception and design, Analysis and interpretation of data.

MH, Acquisition of data, Analysis and interpretation of data.

AM, Acquisition of data, Analysis and interpretation of data.

JS, Acquisition of data, Analysis and interpretation of data.

AFM, Acquisition of data, Analysis and interpretation of data.

FvN, Acquisition of data, Analysis and interpretation of data.

DM, Conception and design, Acquisition of data, Analysis and interpretation of data.

EAN, designed the experiments; wrote the manuscript with help from all co-authors, Conception and design, Analysis and interpretation of data, Drafting or revising the article.

Additional files {#s6}
================

10.7554/eLife.12187.018

###### Related to [Figure 1](#fig1){ref-type="fig"}.

IC~50~ profile of BAY-320 and BAY-524.

**DOI:** [http://dx.doi.org/10.7554/eLife.12187.018](10.7554/eLife.12187.018)

10.7554/eLife.12187.019

###### Related to [Figure 1](#fig1){ref-type="fig"}.

In vitro kinase-selectivity profile of BAY-320 on a panel of 222 human kinases (Eurofins kinase profiler screen, Millipore). Shown are percentages of residual kinase activity at 10 µM BAY-320 and 10 µM ATP.

**DOI:** [http://dx.doi.org/10.7554/eLife.12187.019](10.7554/eLife.12187.019)

10.7554/eLife.12187.020

###### Related to [Figure 1](#fig1){ref-type="fig"}.

In vitro kinase-selectivity profile of BAY-320. Results are based on an active site-directed competition-binding assay using a panel of 403 human kinases (DiscoverX Kinome Scan, Lead Hunter). Results show ligand binding at 300 and 1000 nM BAY-320 relative to control condition.

**DOI:** [http://dx.doi.org/10.7554/eLife.12187.020](10.7554/eLife.12187.020)
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Decision letter

Pines

Jon

Reviewing editor

The Gurdon Institute

,

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors (Jonathon Pines). The evaluation has been overseen by the Reviewing Editor and Ivan Dikic as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this study the authors have developed small molecule inhibitors that specifically inhibit the Bub1 kinase. They demonstrate the specificity of their inhibitors in vitro on a panel of kinases, and in vivo using phosphorylation of Histone H2A threonine 120 as a read out. They show that inhibiting Bub1 causes mild effects on the timing of mitosis and on chromosome congression, but causes persistent cohesion of chromosomes arms concomitant with the chromosome passenger complex remaining on the arms. Although the effects of the Bub1 kinase inhibitors alone only mildly affect mitosis, they have a synergistic effect with low doses of taxol.

Essential revisions:

All three reviewers recognised the quality of the study, and that specific Bub1 kinase inhibitors would be very useful research tools. There were two major experimental concerns, however:

1\) More evidence for the specificity of the compounds should be presented. At present this mostly consists of a patent and kinase assays on a panel of kinases.

2\) Are the effects of the compounds in cells specific to inhibiting Bub1? The authors are using a relatively high concentration of the inhibitors (3 and 7 μM for BAY-320 and BAY-524, respectively), and the toxic concentration is 10 μM. Moreover, there is still some residual H2A-T120 phosphorylation ([Figure 1C and D](#fig1){ref-type="fig"}), which suggests Bub1 activity is not maximally inhibited under these conditions.

Please address these concerns by providing further experimental data. For example, what are the phenotypes of cells treated with the inhibitors in which Bub1 has been depleted and rescued with a kinase-dead construct? If the inhibitors are specific to Bub1 there should be no further effect of the inhibitors.

In addition to this experimental concern, the reviewers suggest some re-writing is required to clarify what is currently known about the function of Bub1 kinase activity. One reviewer makes the following suggestions:

"I would suggest that much of the general introductory material in paragraphs 1 and 2 be condensed. Also, the last paragraph that summarises the results can be replaced by a single sentence, e.g. 'To address the role of Bub1 kinase activity we characterised two novel inhibitors BAY-320 and BAY-524'. Condensing this text will then allow the authors to provide more detail with regards to what is known about Bub1. For example, in the Results they describe Sgo1, that H2A is a substrate, the link with Haspin etc.; this should all be in the Introduction. Also, what is the prior art regarding Bub1\'s kinase activity? They say it is controversial but I don\'t think that is sufficient. Indeed, there is literature that supports the authors' claims and this should be included. By way of an example, Perera at al deleted Bub1 in MEFs and added back kinase-dead mutants showing that a catalytic mutant or a mutant lacking the entire kinase domain restored BubR1 localisation, SAC function and chromosome alignment but failed to restore Sgo1 localisation. Klebig et al. described similar findings using an RNAi-complementation assay. Similarly, McGuinness et al. showed that in meiosis I, a Bub1 mutant lacking the entire kinase domain restored SAC function. There are other primary papers that should be cited here, e.g. describing work in various model systems. NB, as alluded to above, the authors could highlight the technical challenges with complementation assays as a means of justifying the use of small molecule inhibitors."

10.7554/eLife.12187.022

Author response

Essential revisions:

All three reviewers recognised the quality of the study, and that specific Bub1 kinase inhibitors would be very useful research tools. There were two major experimental concerns, however:

1\) More evidence for the specificity of the compounds should be presented. At present this mostly consists of a patent and kinase assays on a panel of kinases.

In the original manuscript we had reported the results of inhibition assays on a panel of 222 protein kinases. To further document the specificity and selectivity of the Bub1 inhibitors we have now performed two additional experiments:

Firstly, using BAY-320 we have conducted an inhibitor-binding assay (DiscoveRx assay) on a vast panel of human kinases, including mitotic kinases. As we show in the new [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}, BAY-320 showed exquisite binding to Bub1 and at most marginal interaction with any one of 407 other human kinases. This survey thus demonstrates high selectivity of BAY-320 for its target.

Secondly, we have generated dose-response curves using an "in-cell western assay" detecting phospho-Thr 120 signals in mitotically arrested HeLa cells (see new [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). This assay yielded an IC~50~ value of 379 +/- 156 nM for BAY-320 (at cellular levels of ATP), in reasonable agreement with the IC~50~ determined by in vitro phosphorylation at 2mM ATP (680 nM).

As with all small molecules, definitive proof of selectivity in a cellular context is nearly impossible to obtain. However, we emphasize that both BAY-320 and BAY-524 have gone through extensive validation in the course of drug development at Bayer; this, combined with the absence of any unpredicted phenotypic effects, makes us highly confident of the selectivity of these compounds.

2\) Are the effects of the compounds in cells specific to inhibiting Bub1? The authors are using a relatively high concentration of the inhibitors (3 and 7 μM for BAY-320 and BAY-524, respectively), and the toxic concentration is 10 μM. Moreover, there is still some residual H2A-T120 phosphorylation ([Figure 1C and D](#fig1){ref-type="fig"}), which suggests Bub1 activity is not maximally inhibited under these conditions.

Please address these concerns by providing further experimental data. For example, what are the phenotypes of cells treated with the inhibitors in which Bub1 has been depleted and rescued with a kinase-dead construct? If the inhibitors are specific to Bub1 there should be no further effect of the inhibitors.

As we stated above (see response to concern No. 1), dose-response curves obtained from "in-cell western" assays show maximal reduction of Thr120 phosphorylation between 3.0 and 10.0 μM, a concentration range used in key experiments throughout this study. These new results are in full agreement with the data shown in [Figure 1C and D](#fig1){ref-type="fig"}, even though they were obtained using different methodology and a different anti-phospho-Thr120 antibody. Thus, although the argument of 'residual activity' is difficult to rigorously exclude, we are confident that an increase in concentration \>10 μM would be unlikely to change the outcome of our experiments.

To further document the specificity of the phenotypes produced by BAY-B320 and BAY-B524 treatment, we have included additional data to complement the results shown in [Figure 1C and D](#fig1){ref-type="fig"} (see new Figure---figure supplement 1 A and B). Specifically, we compared the effects of inhibitor treatment on Thr120 H2A phosphorylation and Aurora B signals at centromeres/KTs over a vast range of inhibitor concentrations. Interestingly, changes in H2A phosphorylation and Aurora B centromere/KT levels correlate nicely at all concentrations below 10 μM, but no further effect on Aurora B could be observed at concentrations above 10 μM. This argues that, once Bub1 is maximally inhibited (at 10 μM), no further impact on Aurora B localization is triggered by our compounds, attesting to specificity.

From a more general perspective, we emphasize that the two Bub1 inhibitors did not trigger any phenotypes that could not also be observed in response to Bub1 depletion, arguing strongly against off-target effects. Thus, we are confident that our observations specifically reflect Bub1 inhibition.

We have also carefully considered the suggested rescue experiment, but in the end decided against attempting it. Although such an experiment appears plausible at first glance, it would be technically very difficult and, in our opinion, not necessarily conclusive. Any additional effect produced by Bub1 inhibition in a cell depleted of wild-type Bub1 (and rescued by catalytically inactive Bub1) could in fact be attributed to inhibition of residual, depletion-resistant wild-type Bub1.

In addition to this experimental concern, the reviewers suggest some re-writing is required to clarify what is currently known about the function of Bub1 kinase activity. One reviewer makes the following suggestions:"I would suggest that much of the general introductory material in paragraphs 1 and 2 be condensed. Also, the last paragraph that summarises the results can be replaced by a single sentence, e.g. 'To address the role of Bub1 kinase activity we characterised two novel inhibitors BAY-320 and BAY-524'. Condensing this text will then allow the authors to provide more detail with regards to what is known about Bub1. For example, in the Results they describe Sgo1, that H2A is a substrate, the link with Haspin etc.; this should all be in the Introduction. Also, what is the prior art regarding Bub1\'s kinase activity? They say it is controversial but I don\'t think that is sufficient. Indeed, there is literature that supports the authors' claims and this should be included. By way of an example, Perera at al deleted Bub1 in MEFs and added back kinase-dead mutants showing that a catalytic mutant or a mutant lacking the entire kinase domain restored BubR1 localisation, SAC function and chromosome alignment but failed to restore Sgo1 localisation. Klebig et al. described similar findings using an RNAi-complementation assay. Similarly, McGuinness et al. showed that in meiosis I, a Bub1 mutant lacking the entire kinase domain restored SAC function. There are other primary papers that should be cited here, e.g. describing work in various model systems."

We have re-written major parts of the Introduction and Results sections. In particular, we have shortened the opening paragraphs of the Introduction, moved introductory material from the former Results section, and discussed prior studies on the role of Bub1 activity in more detail. We are grateful for these referee suggestions and feel that the text of our revised manuscript has gained in clarity.

"NB, as alluded to above, the authors could highlight the technical challenges with complementation assays as a means of justifying the use of small molecule inhibitors."

To address this comment, we have added a sentence on technical challenges of genetic studies and advantages of small molecule inhibitors (Discussion).

[^1]: These authors contributed equally to this work.
